JP2013532665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532665A5 JP2013532665A5 JP2013520933A JP2013520933A JP2013532665A5 JP 2013532665 A5 JP2013532665 A5 JP 2013532665A5 JP 2013520933 A JP2013520933 A JP 2013520933A JP 2013520933 A JP2013520933 A JP 2013520933A JP 2013532665 A5 JP2013532665 A5 JP 2013532665A5
- Authority
- JP
- Japan
- Prior art keywords
- antigenic composition
- pathogen
- region
- composition according
- bacteroides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000890 antigenic effect Effects 0.000 claims 19
- 230000001717 pathogenic effect Effects 0.000 claims 15
- 244000052769 pathogen Species 0.000 claims 13
- 241000606125 Bacteroides Species 0.000 claims 6
- 241000588724 Escherichia coli Species 0.000 claims 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 241000701022 Cytomegalovirus Species 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 241001263478 Norovirus Species 0.000 claims 3
- 241000702670 Rotavirus Species 0.000 claims 3
- 241000700584 Simplexvirus Species 0.000 claims 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- 241000606124 Bacteroides fragilis Species 0.000 claims 2
- 241000193163 Clostridioides difficile Species 0.000 claims 2
- 241000193468 Clostridium perfringens Species 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims 2
- 241000607768 Shigella Species 0.000 claims 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims 2
- 244000309743 astrovirus Species 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 241000186046 Actinomyces Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 206010009895 Colitis ischaemic Diseases 0.000 claims 1
- 206010056979 Colitis microscopic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 241000588914 Enterobacter Species 0.000 claims 1
- 241000605909 Fusobacterium Species 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 241000191992 Peptostreptococcus Species 0.000 claims 1
- 241001135223 Prevotella melaninogenica Species 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 241000589886 Treponema Species 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 claims 1
- 241000607447 Yersinia enterocolitica Species 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000027138 indeterminate colitis Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 201000008222 ischemic colitis Diseases 0.000 claims 1
- 208000004341 lymphocytic colitis Diseases 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940098232 yersinia enterocolitica Drugs 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/843,296 | 2010-07-26 | ||
| US12/843,296 US8501198B2 (en) | 2004-06-07 | 2010-07-26 | Tissue targeted antigenic activation of the immune response to treat cancers |
| US41137110P | 2010-11-08 | 2010-11-08 | |
| US61/411,371 | 2010-11-08 | ||
| US13/019,208 | 2011-02-01 | ||
| US13/019,208 US9107864B2 (en) | 2004-06-07 | 2011-02-01 | Tissue targeted antigenic activation of the immune response to treat cancers |
| US201161500836P | 2011-06-24 | 2011-06-24 | |
| US61/500,836 | 2011-06-24 | ||
| PCT/CA2011/000851 WO2012012874A1 (en) | 2010-07-26 | 2011-07-26 | Immunogenic anti-inflammatory compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016082754A Division JP6129378B2 (ja) | 2010-07-26 | 2016-04-18 | 免疫原性抗炎症組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532665A JP2013532665A (ja) | 2013-08-19 |
| JP2013532665A5 true JP2013532665A5 (enExample) | 2014-09-18 |
| JP5923501B2 JP5923501B2 (ja) | 2016-05-24 |
Family
ID=45529307
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520933A Active JP5923501B2 (ja) | 2010-07-26 | 2011-07-26 | 免疫原性抗炎症組成物 |
| JP2016082754A Active JP6129378B2 (ja) | 2010-07-26 | 2016-04-18 | 免疫原性抗炎症組成物 |
| JP2017078054A Expired - Fee Related JP6471188B2 (ja) | 2010-07-26 | 2017-04-11 | 免疫原性抗炎症組成物 |
| JP2019008043A Pending JP2019070040A (ja) | 2010-07-26 | 2019-01-21 | 免疫原性抗炎症組成物 |
| JP2021016355A Pending JP2021088568A (ja) | 2010-07-26 | 2021-02-04 | 免疫原性抗炎症組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016082754A Active JP6129378B2 (ja) | 2010-07-26 | 2016-04-18 | 免疫原性抗炎症組成物 |
| JP2017078054A Expired - Fee Related JP6471188B2 (ja) | 2010-07-26 | 2017-04-11 | 免疫原性抗炎症組成物 |
| JP2019008043A Pending JP2019070040A (ja) | 2010-07-26 | 2019-01-21 | 免疫原性抗炎症組成物 |
| JP2021016355A Pending JP2021088568A (ja) | 2010-07-26 | 2021-02-04 | 免疫原性抗炎症組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10130692B2 (enExample) |
| EP (3) | EP4324526A3 (enExample) |
| JP (5) | JP5923501B2 (enExample) |
| KR (2) | KR101916853B1 (enExample) |
| CN (2) | CN105797145A (enExample) |
| AU (3) | AU2016238866B2 (enExample) |
| CA (2) | CA3255684A1 (enExample) |
| DK (1) | DK2598165T3 (enExample) |
| ES (2) | ES2645509T3 (enExample) |
| IL (2) | IL224048B (enExample) |
| MX (1) | MX345240B (enExample) |
| MY (1) | MY188328A (enExample) |
| NZ (2) | NZ702796A (enExample) |
| PL (1) | PL2598165T3 (enExample) |
| RU (2) | RU2722357C2 (enExample) |
| SG (2) | SG10201604175XA (enExample) |
| WO (1) | WO2012012874A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| ES2645509T3 (es) | 2010-07-26 | 2017-12-05 | Qu Biologics Inc | Composiciones antiinflamatorias inmunogénicas |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| WO2014059313A1 (en) * | 2012-10-12 | 2014-04-17 | Lehigh University | Thermally stable enzymes, compositions thereof and methods of using same |
| WO2014160266A1 (en) * | 2013-03-14 | 2014-10-02 | Coronado Biosciences, Inc. | Treatment of type i diabetes mellitus using helminthic parasite preparations |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| SG10201912301XA (en) | 2013-11-04 | 2020-02-27 | Uti Lp | Methods and compositions for sustained immunotherapy |
| CA3254723A1 (en) * | 2014-05-02 | 2025-04-15 | Qu Biologics Inc | ANTIMICROBIAL IMMUNOMODULATION |
| CN107073106B (zh) * | 2014-11-10 | 2021-11-23 | 奥夫尔·曼德尔波姆 | 用于治疗泌尿生殖系统癌症的减毒或失活病原性大肠杆菌 |
| ES2658310T3 (es) | 2014-12-23 | 2018-03-09 | 4D Pharma Research Limited | Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación |
| EP3193901B1 (en) | 2014-12-23 | 2018-04-04 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US12011480B2 (en) | 2015-05-06 | 2024-06-18 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
| PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| MA55434B1 (fr) | 2015-06-15 | 2022-02-28 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| TWI759266B (zh) | 2015-06-15 | 2022-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物之用途 |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| CN105176882B (zh) * | 2015-10-17 | 2018-09-21 | 福清市默克兽医院 | 一种牛摩氏摩根菌性关节炎灭活疫苗及其制备方法 |
| MA45287A (fr) | 2015-11-20 | 2018-08-22 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| PT3313423T (pt) | 2016-03-04 | 2019-07-10 | 4D Pharma Plc | Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral |
| WO2017185180A1 (en) | 2016-04-26 | 2017-11-02 | Qu Biologics Inc. | Therapeutically triggering an innate immune response in a target tissue |
| CN105797153A (zh) * | 2016-05-02 | 2016-07-27 | 浙江农林大学 | 兽用疫苗免疫佐剂及其制备与应用方法 |
| CN106011007A (zh) * | 2016-06-06 | 2016-10-12 | 余国华 | 多联耐药菌免疫活性蛋白及其制备方法和用途 |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10596206B1 (en) * | 2017-03-14 | 2020-03-24 | Cornell University | Probiotic compositions and methods of use |
| RS61872B1 (sr) | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| WO2018217764A1 (en) * | 2017-05-22 | 2018-11-29 | Kansas State University Research Foundation | Microbiome transplantation |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| EP3638271B1 (en) | 2017-06-14 | 2020-10-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| JP6840272B2 (ja) | 2017-06-14 | 2021-03-10 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| RS63393B1 (sr) | 2017-06-14 | 2022-08-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| US11077179B2 (en) * | 2017-08-10 | 2021-08-03 | Epicgenetics, Inc. | Method for treating fibromyalgia and chronic fatigue syndrome |
| CN111741746A (zh) | 2017-11-29 | 2020-10-02 | 乌第有限合伙公司 | 治疗自身免疫性疾病的方法 |
| US12491153B2 (en) | 2018-01-03 | 2025-12-09 | Qu Biologics Inc. | Innate targeting of adoptive cellular therapies |
| EP3817771A4 (en) * | 2018-07-03 | 2022-03-23 | Artizan Biosciences, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE |
| EP3990000A1 (en) * | 2019-06-28 | 2022-05-04 | Nantcell, Inc. | Pharmaceutical compositions to enhance phagocytosis without inflammation |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| CN116875516B (zh) * | 2023-09-06 | 2023-12-08 | 上海上药信谊药厂有限公司 | 青春双歧杆菌ba-3及其在抗衰老、抗氧化和抗炎中的应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3928565A (en) | 1971-10-19 | 1975-12-23 | Yuzuru Homma | Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties |
| US4326452A (en) | 1977-10-24 | 1982-04-27 | Matsushita Electric Industrial Co., Ltd. | Fluid diverting assembly |
| JPS5946493B2 (ja) | 1978-03-31 | 1984-11-13 | 株式会社三和化学研究所 | 異種死菌体混合物を有効成分とする抗腫瘍剤 |
| JPS56108716A (en) | 1980-01-30 | 1981-08-28 | Sanwa Kagaku Kenkyusho:Kk | Antiviral agent containing different kind dead cell mixture as effective component |
| JPS5839624A (ja) | 1981-09-02 | 1983-03-08 | Meiji Seika Kaisha Ltd | 抗腫瘍剤 |
| JPS6012071A (ja) | 1983-06-30 | 1985-01-22 | 東レ株式会社 | 抗腫瘍作用を有する体液処理剤 |
| US4880626A (en) | 1985-01-18 | 1989-11-14 | Mcmichael John | Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome |
| FR2683529B1 (fr) | 1991-11-12 | 1994-02-04 | Bretagne Occidentale Universite | Composes pharmaceutiques gem-diphosphonates analogues du cis-platine. |
| US5292513A (en) | 1992-05-18 | 1994-03-08 | Anthony G. Gristina | Method for nonspecific cellular immune stimulation |
| US5652332A (en) * | 1993-03-12 | 1997-07-29 | Xoma | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
| GB9406301D0 (en) | 1994-03-30 | 1994-05-25 | Univ London | Immunotherapeutic agent and its use |
| US6902743B1 (en) * | 1995-05-22 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix |
| WO1997036614A1 (en) * | 1996-03-29 | 1997-10-09 | Terman David S | Polymerized staphylococcal protein a for treatment of diseases |
| US6348586B1 (en) | 1996-07-25 | 2002-02-19 | The Trustees Of Columbia University In The City Of New York | Unique associated Kaposi's sarcoma virus sequences and uses thereof |
| US20020128240A1 (en) | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
| US6028060A (en) | 1997-01-29 | 2000-02-22 | Vanderbilt University | Treatment of chronic inflammatory diseases with CM101/GBS toxin |
| EP2340840B1 (en) | 1998-03-27 | 2012-08-29 | Oregon Health Sciences University | Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases |
| GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| TWI306760B (en) | 2000-08-07 | 2009-03-01 | Abbott Lab | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same |
| US7118740B1 (en) | 2000-09-22 | 2006-10-10 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
| WO2002036611A2 (en) * | 2000-11-01 | 2002-05-10 | The Regents Of The University Of California | Immunomodulatory peptides derived from heat shock proteins and uses thereof |
| GB2370770B (en) * | 2001-01-03 | 2005-06-01 | Simon Connolly | Uses of Streptococcus Vaccines |
| FR2822071B1 (fr) | 2001-03-15 | 2005-07-01 | Pf Medicament | Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques |
| KR20040030785A (ko) * | 2001-07-02 | 2004-04-09 | 화이자 프로덕츠 인크. | 마이코플라즈마 하이오뉴모니애로의 1회 투여량 예방접종 |
| US7273602B2 (en) | 2001-07-19 | 2007-09-25 | Akira Hayashi | Immunotherapy for humans |
| AU2002329043A1 (en) * | 2001-07-30 | 2003-02-24 | Claudio De Simone | Treatment of radiation-induced diarrhea with probiotics |
| EP1281767A3 (en) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
| AU2002353366A1 (en) | 2001-12-10 | 2003-06-23 | Bakulesh Mafatlal Khamar | The process of manufacturing a pharmaceutical composition useful for management of cancer |
| WO2003063593A1 (en) | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
| US20060051380A1 (en) | 2002-02-06 | 2006-03-09 | The Johns Hopkins University | Methods and compositions for the targeting of a systemic immune response to specific organs or tissues |
| JP2005531289A (ja) | 2002-02-15 | 2005-10-20 | アゲルプ ファーマ ゲーエムベーハー | Ｓ．ａｕｒｅｕｓエンテロトキシンＢ由来の免疫調節ペプチド |
| US20060147477A1 (en) | 2002-06-11 | 2006-07-06 | Glaxo Group Limited | Immunogenic compositions |
| JP4618970B2 (ja) | 2002-08-02 | 2011-01-26 | マルホ株式会社 | 肛門圧低下外用剤 |
| IL152127A0 (en) | 2002-10-06 | 2003-05-29 | Bio Balance Corp | Probiotic compositions for the treatment of inflammatory bowel disease |
| US7179460B2 (en) * | 2002-12-05 | 2007-02-20 | Danisco A/S | Bacterial composition and its use |
| NZ569331A (en) * | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
| AR043692A1 (es) | 2003-02-06 | 2005-08-10 | Novartis Ag | 2-cianopirrolopirimidinas y sus usos farmaceuticos |
| GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
| EP1631312B1 (en) * | 2003-04-23 | 2008-09-10 | Medarex, Inc. | Compositions and methods for the therapy of inflammatory bowel disease |
| CN1332018C (zh) * | 2003-11-03 | 2007-08-15 | 安徽龙科马生物制药有限责任公司 | 冻干母牛分枝杆菌制剂（微卡）及其制备方法和用途 |
| US20050100559A1 (en) * | 2003-11-07 | 2005-05-12 | The Procter & Gamble Company | Stabilized compositions comprising a probiotic |
| US7413728B2 (en) * | 2003-11-14 | 2008-08-19 | Ucl Biomedica Plc | Immune modulator |
| US20050175630A1 (en) | 2003-12-23 | 2005-08-11 | Eyal Raz | Immunogenic compositions and methods of use thereof |
| EP1586330A1 (en) | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US8034359B2 (en) * | 2004-06-07 | 2011-10-11 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to cancers |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| PL1765391T3 (pl) * | 2004-06-07 | 2013-08-30 | Qu Biologics Inc | Kompozycje bakteryjne do leczenia nowotworów |
| US8029777B2 (en) * | 2004-08-13 | 2011-10-04 | Marshall Barry J | Helicobacter system and uses thereof |
| EP1789094B1 (en) * | 2004-08-13 | 2014-12-10 | MARSHALL, Barry J. | Bacterial delivery system |
| JP5234445B2 (ja) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
| US8092793B2 (en) | 2004-12-15 | 2012-01-10 | Qingdao East Sea Pharmaceuticals, Ltd. | Treating inflammatory bowel disease with live bacteria |
| CA2531261A1 (en) * | 2005-12-21 | 2007-06-21 | Institut Pasteur | Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria |
| CN101351124B (zh) | 2005-12-29 | 2014-09-03 | 希尔氏宠物营养品公司 | 用于改变动物的肠道菌群的方法 |
| EP2040724B1 (en) * | 2006-05-18 | 2011-10-05 | Biobalance Llc | Biotherapeutic compositions comprising probiotic escherichia coli and metronidazole and uses thereof |
| EP2056864B1 (en) * | 2006-08-28 | 2013-12-11 | Omnio Healer AB | Candidates against infection |
| NZ576590A (en) * | 2006-10-27 | 2012-08-31 | Qu Biolog Inc | Tissue targeted antigenic activation of the immune response to treat cancers |
| CA2997459C (en) * | 2006-10-27 | 2020-09-22 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to cancers |
| CN101085347B (zh) * | 2007-06-15 | 2010-05-19 | 东南大学 | 甲型肝炎-乙型肝炎-戊型肝炎联合疫苗 |
| JP5249326B2 (ja) * | 2007-07-23 | 2013-07-31 | ワクチン リサーチ インターナショナル ピーエルシー | 不活化ブドウ球菌全細胞ワクチン |
| WO2009021977A1 (en) | 2007-08-16 | 2009-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human specific escherichia coli strains |
| HUP0700552A2 (en) * | 2007-08-27 | 2009-03-30 | Janos Dr Feher | Method and composition inhibiting inflammation |
| EP2085466A1 (en) * | 2008-01-29 | 2009-08-05 | AEterna Zentaris GmbH | Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof |
| WO2010068413A1 (en) * | 2008-11-25 | 2010-06-17 | Emergent Product Development Gaithersburg Inc. | Chlamydia vaccine comprising htra polypeptides |
| BRPI0924902A2 (pt) | 2009-03-05 | 2015-07-07 | Probiotical Spa | Linhagens de bactérias com alta atividade anti-inflamatória |
| ES2645509T3 (es) | 2010-07-26 | 2017-12-05 | Qu Biologics Inc | Composiciones antiinflamatorias inmunogénicas |
| JP6012071B2 (ja) | 2012-12-03 | 2016-10-25 | 太平洋セメント株式会社 | 塩素バイパス排ガスの処理方法 |
-
2011
- 2011-07-26 ES ES11811677.1T patent/ES2645509T3/es active Active
- 2011-07-26 EP EP23205355.3A patent/EP4324526A3/en active Pending
- 2011-07-26 KR KR1020137004909A patent/KR101916853B1/ko active Active
- 2011-07-26 NZ NZ702796A patent/NZ702796A/en not_active IP Right Cessation
- 2011-07-26 MX MX2013001032A patent/MX345240B/es active IP Right Grant
- 2011-07-26 EP EP11811677.1A patent/EP2598165B1/en active Active
- 2011-07-26 MY MYPI2013000246A patent/MY188328A/en unknown
- 2011-07-26 RU RU2016106134A patent/RU2722357C2/ru active
- 2011-07-26 JP JP2013520933A patent/JP5923501B2/ja active Active
- 2011-07-26 SG SG10201604175XA patent/SG10201604175XA/en unknown
- 2011-07-26 CN CN201610090938.6A patent/CN105797145A/zh active Pending
- 2011-07-26 EP EP17163849.7A patent/EP3235506B1/en active Active
- 2011-07-26 KR KR1020187029524A patent/KR102157718B1/ko active Active
- 2011-07-26 CA CA3255684A patent/CA3255684A1/en active Pending
- 2011-07-26 RU RU2013108248/15A patent/RU2581922C2/ru active
- 2011-07-26 ES ES17163849T patent/ES2971415T3/es active Active
- 2011-07-26 DK DK11811677.1T patent/DK2598165T3/en active
- 2011-07-26 CA CA2804709A patent/CA2804709A1/en active Pending
- 2011-07-26 NZ NZ606490A patent/NZ606490A/en unknown
- 2011-07-26 CN CN201180045079.4A patent/CN103140238B/zh active Active
- 2011-07-26 SG SG2013006077A patent/SG187201A1/en unknown
- 2011-07-26 WO PCT/CA2011/000851 patent/WO2012012874A1/en not_active Ceased
- 2011-07-26 PL PL11811677T patent/PL2598165T3/pl unknown
-
2012
- 2012-01-26 US US13/359,441 patent/US10130692B2/en active Active
- 2012-12-31 IL IL224048A patent/IL224048B/en active IP Right Grant
-
2016
- 2016-04-18 JP JP2016082754A patent/JP6129378B2/ja active Active
- 2016-10-05 AU AU2016238866A patent/AU2016238866B2/en active Active
-
2017
- 2017-04-11 JP JP2017078054A patent/JP6471188B2/ja not_active Expired - Fee Related
-
2018
- 2018-10-19 AU AU2018250480A patent/AU2018250480B2/en not_active Ceased
-
2019
- 2019-01-21 JP JP2019008043A patent/JP2019070040A/ja active Pending
-
2020
- 2020-09-02 IL IL277110A patent/IL277110B2/en unknown
-
2021
- 2021-02-04 JP JP2021016355A patent/JP2021088568A/ja active Pending
- 2021-06-03 AU AU2021203627A patent/AU2021203627B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532665A5 (enExample) | ||
| Ulfman et al. | Effects of bovine immunoglobulins on immune function, allergy, and infection | |
| Colombel et al. | Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial | |
| IL277110B2 (en) | Immunogenic anti-inflammatory preparations | |
| Mack | Probiotics in inflammatory bowel diseases and associated conditions | |
| Isaacs et al. | Treatment of inflammatory bowel disease with antibiotics | |
| US20170008957A1 (en) | Antibody therapeutics with local activity in the digestive tract | |
| JP2012121878A5 (enExample) | ||
| JP2017501848A5 (enExample) | ||
| Richards et al. | Inhibition of invasive salmonella by orally administered IgA and IgG monoclonal antibodies | |
| JP2015180701A (ja) | インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用 | |
| Ngo et al. | Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety | |
| CN113329771A (zh) | 治疗炎症性和自身免疫性疾病的组合物和方法 | |
| Buness et al. | Oral vancomycin therapy in a child with primary sclerosing cholangitis and severe ulcerative colitis | |
| Lichtenstein et al. | The current place of probiotics and prebiotics in the treatment of pouchitis | |
| Wang et al. | Gut‑liver axis in liver disease: From basic science to clinical treatment | |
| Shen et al. | COVID-19 and gut injury | |
| JP2020517671A5 (enExample) | ||
| JP2013544795A5 (enExample) | ||
| Theocharidou et al. | Challenges in liver transplantation in the context of a major pandemic | |
| JP2017521490A5 (enExample) | ||
| Osadchuk et al. | Erosive and ulcerative lesions of the digestive tract: optimization of diagnosis and management tactics | |
| Doorduin et al. | P-glycoprotein activity in the blood–brain barrier is affected by virus-induced neuroinflammation and antipsychotic treatment | |
| Ma et al. | Fecal microbiota transplantation: A promising treatment strategy for chronic liver disease | |
| Günendi et al. | Long term use of leflunomide as a cause of severe diarrhea? |